Bernardi S, Marcuzzi A, Piscianz E, Tommasini A, Fabris B. The Complex Interplay between Lipids, Immune System and Interleukins in Cardio-Metabolic Diseases. Int J Mol Sci 2018;19(12)

Bernardi S, Bossi F, Toffoli B, Giudici F, Bramante A, Furlanis G, Stenner E, Secchiero P, Zauli G, Carretta R, Fabris B. Association between thyroid hormones and TRAIL. Clin Biochem 2017;50(16-17):972-976.

Bernardi S, Toffoli B, Bossi F, Candido R, Stenner E, Carretta R, Barbone F, Fabris B. Circulating osteoprotegerin is associated with chronic kidney disease in hypertensive patients. BMC Nephrol 2017;18(1):219.

Bossi F, Bernardi S, Zauli G, Secchiero P, Fabris B. TRAIL modulates the immune system and protects against the development of diabetes. J Immunol Res 2015;2015:680749.

Bernardi S, Fabris B, Thomas M, Toffoli B, Tikellis C, Candido R, Catena C, Mulatero P, Barbone F, Radillo O, Zauli G, Secchiero P. Osteoprotegerin increases in metabolic syndrome and promotes adipose tissue proinflammatory changes. Mol Cell Endocrinol 2014;394(1-2):13-20.

Bernardi S, Zauli G, Tikellis C, Candido R, Fabris B, Secchiero P, Cooper ME, Thomas MC. TNF-related apoptosis-inducing ligand significantly attenuates metabolic abnormalities in high-fat-fed mice reducing adiposity and systemic inflammation. Clin Sci (Lond) 2012;123(9):547-55.

Bernardi S, Milani D, Fabris B, Secchiero P, Zauli G. TRAIL as biomarker and potential therapeutic tool for cardiovascular diseases. Curr Drug Targets 2012;13(9):1215-21.

Toffoli B, Bernardi S, Candido R, Zacchigna S, Fabris B, Secchiero P. TRAIL shows potential cardioprotective activity. Invest New Drugs 2012;30(3):1257-60.

Toffoli B, Bernardi S, Candido R, Sabato N, Carretta R, Corallini F, Secchiero P, Zauli G, Fabris B. Osteoprotegerin induces morphological and functional alterations in mouse pancreatic islets. Mol Cell Endocrinol 2011;331(1):136-42.

Toffoli B, Pickering RJ, Tsorotes D, Wang B, Bernardi S, Kantharidis P, Fabris B, Zauli G, Secchiero P, Thomas MC. Osteoprotegerin promotes vascular fibrosis via a TGF-?1 autocrine loop. Atherosclerosis 2011;218(1):61-8.

Zauli G, Toffoli B, di Iasio MGrazia, Celeghini C, Fabris B, Secchiero P. Treatment with recombinant tumor necrosis factor-related apoptosis-inducing ligand alleviates the severity of streptozotocin-induced diabetes. Diabetes 2010;59(5):1261-5.